Use of Multifactorial Treatments to Address the Challenge of Translating Experimental Myocardial Infarct Reduction Strategies

Myocardial tissue damage that occurs during an ischemic event leads to a spiraling deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known efficacious strategy and is the most commonly used treatment to reduce injury and prevent remodeling. However, timing...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2019-03, Vol.20 (6), p.1449
Main Authors: Horton, Julie L, Virag, Jitka
Format: Article
Language:English
Subjects:
Animals
cardioprotection
Cardiotonic Agents
Combined Modality Therapy
Diabetes
Disease Management
Economic impact
Ephrin-A1 - genetics
Ephrin-A1 - metabolism
Ephrin-A1 - therapeutic use
Ephrin-A1 - ultrastructure
ephrinA1
Heart attacks
Heart failure
Humans
Immunoglobulin Fc Fragments - therapeutic use
Immunoglobulin Fc Fragments - ultrastructure
Ischemia
Ligands
Mortality
Myocardial infarction
Myocardial Infarction - diagnosis
Myocardial Infarction - etiology
Myocardial Infarction - metabolism
Myocardial Infarction - therapy
Oxidation
Patients
Recombinant Fusion Proteins - therapeutic use
Recombinant Fusion Proteins - ultrastructure
Reperfusion
Review
Scars
Socioeconomic factors
therapeutic strategies
Translational Research, Biomedical
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Myocardial tissue damage that occurs during an ischemic event leads to a spiraling deterioration of cardiac muscle structural and functional integrity. Reperfusion is the only known efficacious strategy and is the most commonly used treatment to reduce injury and prevent remodeling. However, timing is critical, and the procedure is not always feasible for a variety of reasons. The complex molecular basis for cardioprotection has been studied for decades but formulation of a viable therapeutic that can significantly attenuate myocardial injury remains elusive. In this review, we address barriers to the development of a fruitful approach that will substantially improve the prognosis of those suffering from this widespread and largely unmitigated disease. Furthermore, we proffer that ephrinA1, a candidate molecule that satisfies many of the important criteria discussed, possesses robust potential to overcome these hurdles and thus offers protection that surpasses the limitations currently observed.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms20061449